Glycogen metabolism in cancer

被引：117

作者：

Zois, Christos E. ^{[2
]}

Favaro, Elena ^{[1
]}

Harris, Adrian L. ^{[2
]}

机构：

[1] Danish Canc Soc Res Ctr, DK-2100 Copenhagen, Denmark

[2] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Dept Oncol,Mol Oncol Labs, Oxford 0X3 9DS, England

来源：

BIOCHEMICAL PHARMACOLOGY | 2014年 / 92卷 / 01期

关键词：

Glycogen metabolism; Hypoxia; Pentose shunt; Cancer; POTENTIAL ANTIDIABETIC AGENTS; ACTIVATED PROTEIN-KINASE; PHOSPHORYLASE INHIBITORS; BINDING DOMAIN; SYNTHASE KINASE-3; MUSCLE CULTURES; ALLOSTERIC SITE; ACYL UREAS; IN-VIVO; LIVER;

D O I：

10.1016/j.bcp.2014.09.001

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Since its identification more than 150 years ago, there has been an extensive characterisation of glycogen metabolism and its regulatory pathways in the two main glycogen storage organs of the body, i.e. liver and muscle. In recent years, glycogen metabolism has also been demonstrated to be upregulated in many tumour types, suggesting it is an important aspect of cancer cell pathophysiology. Here, we provide an overview of glycogen metabolism and its regulation, with a focus on its role in metabolic reprogramming of cancer cells. The various methods to detect glycogen in tumours in vivo are also reviewed. Finally, we discuss the targeting of glycogen metabolism as a strategy for cancer treatment. (C) 2014 Elsevier Inc. All rights reserved.

引用

页码：3 / 11

页数：9

共 91 条

[1]

Physiological Control of Liver Glycogen Metabolism: Lessons from Novel Glycogen Phosphorylase Inhibitors [J].

Agius, L. .

MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2010, 10 (12) :1175-1187

[2]

New hepatic targets for glycaemic control in diabetes [J].

Agius, Loranne .

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 21 (04) :587-605

[3]

Inhibition of glycogenolysis in primary rat hepatocytes by 1,4-dideoxy-1,4-imino-d-arabinitol [J].

Andersen, B ;

Rassov, A ;

Westergaard, N ;

Lundgren, K .

BIOCHEMICAL JOURNAL, 1999, 342 :545-550

[4]

[Anonymous], 2002, Oxidative Phosphorylation

[5]

Design of Glycogen Synthase Kinase-3 Inhibitors: An Overview on Recent Advancements [J].

Arfeen, Minhajul ;

Bharatam, Prasad V. .

CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (26) :4755-4775

[6]

Baba O, 1993, Kokubyo Gakkai Zasshi, V60, P264

[7]

Intervention of hepatic glucose production. Small molecule regulators of potential targets for type 2 diabetes therapy [J].

Barf, T .

MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2004, 4 (08) :897-908

[8]

Molecular mode of inhibition of glycogenolysis in rat liver by the dihydropyridine derivative, BAY R3401 - Inhibition and inactivation of glycogen phosphorylase by an activated metabolite [J].

Bergans, N ;

Stalmans, W ;

Goldmann, S ;

Vanstapel, F .

DIABETES, 2000, 49 (09) :1419-1426

[9]

Development of potent, orally active 1-substituted-3,4-dihydro-2-quinolone glycogen phosphorylase inhibitors [J].

Birch, Alan M. ;

Kenny, Peter W. ;

Oikonomakos, Nikos G. ;

Otterbein, Ludovic ;

Schofield, Paul ;

Whittamore, Paul R. O. ;

Whalley, Dave P. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (02) :394-399

[10]

Allosteric Regulation of Glycogen Synthase Controls Glycogen Synthesis in Muscle [J].

Bouskila, Michale ;

Hunter, Roger W. ;

Ibrahim, Adel F. M. ;

Delattre, Lucie ;

Peggie, Mark ;

van Diepen, Janna A. ;

Voshol, Peter J. ;

Jensen, Jorgen ;

Sakamoto, Kei .

CELL METABOLISM, 2010, 12 (05) :456-466

← 1 2 3 4 5 6 7 8 9 10 →